The Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center is pleased to have funded the following MSK investigators and specific metastasis-related projects and resource acquisitions.
CARM1 Inhibition Alters the Epigenetic Plasticity of Metastatic Breast Cancer Cells
Numerous epigenetic events need to be orchestrated for breast cancer cells to metastasize to remote organs. Significant efforts have been made to identify the epigenetic cues that module metastatic outgrowth. CARM1 is an important epigenetic modulator to which metastatic breast cancer cells are addicted. High levels of CARM1 strongly correlate with breast cancer malignancy. We recently developed CARM1 chemical probes to interrogate CARM1-associated biology. The GMETC grant allowed us to evaluate in vivo efficacy of these compounds against breast cancer metastasis. While these treatments had no effect on the primary lung lesion, they significantly suppressed the secondary metastatic lesion and prolong overall survival. In addition, we conducted multiple sets of scRNA-seq analysis on gene expression profiles of MDA-MB-231 cells and develop in-house machine-learning algorithms dissect subpopulation-associated transcriptomic signatures of invasive cells. We concluded that the invasion capability of MDA-MB-231 cells mainly arises from an invasion-prone subset, 80% of which can be depleted by our CARM1 inhibitors. Differential expression analysis of scRNA-seq data further revealed the single-cell transcriptional signatures of metastasis-addicted genes such as MORC4, S100A2, RPL39, IFI27, ARF6, CHD11, SDPR and KRT18.
The epigenetic control of tumor ecosystem dynamics during PDAC progression
Pancreatic ductal adenocarcinoma (PDAC) is an invariably lethal cancer that arises in the context of a unique tumor microenvironment. This project aimed to examine the dynamic nature and regulation of intratumoral heterogeneity in pancreatic cancer, from its inception through metastasis. To do so, we implemented an integrative in vivo approach that combines single-cell technologies, state-of-the art computational analyses and unique mouse models of pancreatic cancer enabling perturbation of gene function at different disease stages. Our results uncovered that Kras gene mutation and tissue damage (pancreatitis) cooperatively remodel the chromatin landscape of the pancreatic epithelium to produce altered cellular states that distinguish the neoplastic process from physiological regenerative responses (Alonso-Curbelo et al., Nature 2021). Ongoing studies are incorporating novel computational methods that integrate transcriptional and chromatin information to predict cancer-initiating cells and their paths to overcoming key barriers to malignancy: initiation, benign to malignant transition, and metastatic dissemination. Collectively, our work indicates that large-scale epigenomic remodeling events integrating inputs from tissue context (inflammation) and genetics (driver gene mutations) direct the co-reprogramming of pancreatic epithelial cells and their niche early during tumor development, and establishes key cell- and non-cell-autonomous nodes that may pave the way for novel means to intercept and potentially revert the aberrant cell states responsible for PDAC initiation and metastatic progression.
Metabolic crosstalk between melanoma and its microenvironment
There have been astounding advances in the treatment of metastatic melanoma with both targeted therapy and immunotherapy, but unfortunately more than half of people with metastatic melanoma still die of the disease. Therefore, it is important to understand the mechanisms of melanoma metastasis. This wide-ranging effort will explore the role of cellular stress and immune responses on metastasis in melanoma. Researchers also will investigate how the melanoma microenvironment induces metabolic alterations within melanoma cells that directly facilitate cellular invasion and metastasis.
This is the first GMTEC award to include multiple projects. In addition, the research team has applied to the National Institutes of Health for a P01 grant related to this work.
Project 1: Molecular mechanisms, immune responses, and cancer cell metabolism
Santosha Vardhana and Craig Thompson
This project will explore the metabolic consequences of redox regulation and its effect on T cell function within the tumor. It aims to look at the connection between metabolic adaptation in the setting of chronic inflammation and the promotion of immune evasion and metastasis in melanoma. The researchers will examine the role of altered metabolism in promoting immune dysfunction in melanoma. They also seek to determine the contribution of exogenous fatty acids to altered melanoma-specific immune responses.
Project 2: Characterize the role of lipid uptake–induced ER stress in metastasis of melanoma
This project will examine the ability of melanoma cells to metabolize fat as an energy source despite BRAF inhibition. One tool in this research is transgenic zebrafish, which will be used to characterize the role of fat cells in the progression of melanoma. These models will also be used to assess the mechanism of lipid-mediated ER stress in melanoma invasion and study the effects that lipids have on immune cells within the tumor microenvironment. The project will also look at whether blocking SLC27A fatty acid transporter proteins has therapeutic potential, and may ultimately lead to clinical trials evaluating this approach.
Project 3: Enhancing immune-mediated control of melanoma metastasis by modulating glycolytic stress
This project will examine the LDH/lactate axis and the effect of lactate on immune suppression in melanoma. It aims to study the connection between lactate production and the anti-melanoma immune response. It will also investigate whether blocking lactate production can improve T cell responses against melanoma.
Identifying novel drugs that inhibit aRMS metastasis.
The most common pediatric soft tissue sarcoma is rhabdomyosarcoma (RMS), representing 3 to 5 percent of all childhood cancers. Alveolar RMS (aRMS) is its most aggressive form and is associated with expression of PAX3- or PAX7-FOXO1 fusion oncoproteins. Although successive clinical trials have improved survival rates for RMS patients, the outcome with standard treatment for those patients with metastatic or recurrent disease remains bleak. (The five-year survival rate is less than 20 percent.) Moreover, within the last 30 years, there have been no significant changes in treatment, and no precision treatments exist. Hence, there is a critical need to investigate RMS metastasis and to identify novel therapeutic agents for its treatment. This is the goal of the Baylies lab’s work.
With funding from MTECH, the Baylies lab has identified 17 FDA-approved or in-trial drugs that target aRMS metastasis. These drugs, combined with a novel, ongoing screen in a Drosophila aRMS model, reveal 11 pathways essential for disease development. The activity of eight of the identified drugs that affect the RAS-MAPK, PI3K-AKT, and NFkB signaling pathways has been confirmed in this in vivo model. Importantly, the Baylies lab has identified three combinations of these drugs that eliminate or significantly reduce the metastatic potential of aRMS.
Based on these and published data, the Baylies lab is testing the FDA-approved/in-trial drugs that target RAS-MAPK, PI3K-AKT, and NFkB for validation and further characterization in human RMS tumor cell lines and in an aRMS ‘metastasis’ xenograft model. For the human tumor cell lines, the Baylies lab has developed a high throughput, image-based approach in collaboration with Andrew Cohen at Drexel University to assess tumor cell behaviors upon drug treatment (single and combinatorial treatment). The Baylies lab has now identified several FDA-approved/in-trial drugs and drug combinations that preferentially affect different aspects of human metastatic tumor cell behavior, including adhesion, migration, proliferation, or survival. The Baylies lab is now examining these drug combinations in aRMS xenograft models that reproduce aspects of the metastatic process, including survival in the blood stream, extravasion, colonization of different tissue sites, and proliferation at these sites. These experiments provide the critical next step toward patient treatment. Successful completion of these experiments will provide new precision therapeutic agents and regimes for testing in the clinic.
Investigation of the Microenvironmental Transcriptome in Breast to Brain Metastasis.
Role of ESR1 Mutation in Breast Cancer Metastases
Scott W. Lowe
Dissecting the interactions between Smad4 and p53 inactivation in pancreatic cancer metastasis
Strip1 and STRIPAK complexes in cell migration and metastasis
Timothy A. Chan
Large-Scale Analysis and Clinical Application of the Breast Cancer Metastasis Epigenome
Nai-Kong V. Cheung
Genetic Analyses of Secondary CNS Metastases in Neuroblastoma (NB)
Identifying Clinical Tools to Detect SRC as a Critical Moderator of Bone Metastasis Latency in Women with ER Positive
Functional Genomics Analysis of Tumor Dormancy at Metastatic Sites